AG Heine - Hämatologie und Onkologie des Universitätsklinikums Bonn
Pacritinib protects dendritic cells more efficiently than ruxolitinib - Experimental Hematology
Auszeichnung für herausragende Krebsforscher - Centrum für Integrierte Onkologie
Volume 21, Issue 3, Pages (October 2017) - ppt download
Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherap
G-quadruplexes: a promising target for cancer therapy | Molecular Cancer | Full Text
Researchers release the brakes on the immune | EurekAlert!
The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function | PLOS ONE
Team | IMMEI
Krebszentrum CIO Bonn - Ich bin Prof. Annkristin Heine | Facebook
Prof. Dr. med. Annkristin Heine - Hämatologie und Onkologie des Universitätsklinikums Bonn
The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells | SpringerLink
ONLINE Cluster Lecture Series
Immunotherapy as an advance in cancer medicine - Innovations Report
Cardiac MRI in Suspected Acute COVID-19 Myocarditis
Tückischen Blutkrebs effektiv bekämpfen - Centrum für Integrierte Onkologie
Generation and functional characterization of MDSC-like cells
Team | IMMEI
Frontiers | Case report: Complete response to pembrolizumab in a liver metastatic colon adenocarcinoma patient with a novel likely pathogenic germline MSH2 mutation
Clinical and immunological effects of mRNA vaccines in malignant diseases | Molecular Cancer | Full Text
The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function | PLOS ONE
Unter der Leitung von Frau Prof.... - Krebszentrum CIO Bonn | Facebook
Annkristin HEINE | Medical Doctor | Professor | University of Bonn - Medical Center, Bonn | Haematology Oncology | Research profile
PDF) Long-term survival after vaccination with RNA coding for TAA in Renal Cell Carcinoma: update on survival and correlation with immunological response
CIO Bonn - Tumorboards
Frontiers | Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumors
